**Appendix Table C37. Time to event outcomes: Treatment, retinoblastoma**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study (Investigator,****country, year)** | **Record Number** | **Group (N)** | **Outcome** | **Med (mos)** | **1 yr** | **2 yr** | **3 yr** | **4 yr** | **5 yr** |
| Namouni, France, 1997 | 18090 | HSCT (25) | ~70% | 22 months | ~97% | ~70% | ~70% | ~70% | ~70% |
| Dunkel, USA, 2010 | 2149 | HSCT (15) | 67% | 108 months |   |   |   |   | 67% |

**Appendix Table C37. Time to event outcomes: Treatment, retinoblastoma Continued**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study (Investigator,****country, year)** | **Record Number** | **Group (N)** | **Outcome\_2** | **1 yr\_2** | **2 yr\_2** | **3 yr\_2** | **4 yr TRM** | **5 yr\_2** | **Outcome\_3** | **Med (mos)\_3** | **1 yr\_3** | **2 yr\_3** | **3 yr\_3** | **4 yr\_3** | **5 yr\_3** | **Comment** |
| Namouni, France, 1997 | 18090 | HSCT (25) | Intention to treat overall survival n=34 | ~88% | ~60% | ~57% | ~52% | ~52% | Event Free intention to treatn=34 | 37 months | ~88% | ~62% | ~57% | ~53% | ~53% | 8 of 9 excluded died due to CNS involvement |
| Dunkel, USA, 2010 | 2149 | HSCT (15) | retinoblastoma free |  |  |  |  | 67%  | progression free | 10 years |  |  |  |  | 59%  |  |